title: Modification of 35% carbon dioxide hypersensitivity across one week of treatment with clomipramine and fluvoxamine: a double-blind, randomized, placebo-controlled study.
abstract: The effects of short treatments (7 days) with clomipramine and fluvoxamine on the reactivity to inhalations of 35% CO2/65% O2 were compared in 39 panic patients who had positive responses to 35% CO2 inhalations. A double-blind, randomized, placebo-controlled design was applied. Each patient was given the 35% CO2 challenge on days 0 (before starting treatment), 3, and 7. Patients on placebo did not report any significant changes in their reactivity to 35% CO2 across the three sessions, whereas patients on clomipramine and fluvoxamine reported a significant attenuation of the reactivity on day 7. These results indicate that treatments with clomipramine and fluvoxamine decrease hypersensitivity to 35% CO2 after a few days, suggesting a relevant role of the modulation of CO2 sensitivity by the serotonergic system in antipanic properties of these compounds.
authors.affiliation: Department of Neuropsychiatric Sciences, University of Milan, Istituto Scientifico HS Raffaele, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Perna
authors.forename: A
authors.initials: A
authors.lastname: Bertani
authors.forename: A
authors.initials: A
authors.lastname: Gabriele
authors.forename: E
authors.initials: E
authors.lastname: Politi
authors.forename: L
authors.initials: L
authors.lastname: Bellodi
mesh_terms: D000328:Adult; D002245:Carbon Dioxide; D002997:Clomipramine / Q000627:therapeutic use*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D016666:Fluvoxamine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D016584:Panic Disorder / Q000175:diagnosis / Q000188:drug therapy*; D011569:Psychiatric Status Rating Scales; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*
chemical_list: D002245:Carbon Dioxide; D002997:Clomipramine; D016666:Fluvoxamine; D017367:Selective Serotonin Reuptake Inhibitors